A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 149,000 shares of VRTX stock, worth $70.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
149,000
Previous 187,500 20.53%
Holding current value
$70.6 Million
Previous $76.3 Million 18.36%
% of portfolio
0.01%
Previous 0.02%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $99.8 Million - $109 Million
-244,707 Reduced 74.91%
81,973 $34.3 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $103 Million - $123 Million
298,936 Added 1077.48%
326,680 $133 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $9.34 Million - $10 Million
27,631 Added 24452.21%
27,744 $9.65 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $26.3 Million - $29.5 Million
-83,693 Reduced 99.87%
113 $39,000
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $33.9 Million - $38.7 Million
-119,805 Reduced 58.84%
83,806 $26.4 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $54.3 Million - $61 Million
189,846 Added 1379.19%
203,611 $58.8 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $3.77 Million - $4.21 Million
13,765 New
13,765 $3.99 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $46.5 Million - $54.8 Million
-209,986 Reduced 83.13%
42,605 $11.1 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $28.6 Million - $36.1 Million
-161,538 Reduced 39.01%
252,591 $55.5 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $4.45 Million - $4.98 Million
24,539 Added 6.3%
414,129 $75.1 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $249 Million - $294 Million
-1,329,590 Reduced 77.34%
389,590 $78.6 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $49.9 Million - $58.1 Million
240,821 Added 16.29%
1,719,180 $369 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $117 Million - $156 Million
566,347 Added 62.1%
1,478,359 $349 Million
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $119 Million - $141 Million
465,056 Added 104.05%
912,012 $248 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $117 Million - $145 Million
-583,879 Reduced 56.64%
446,956 $106 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $52.7 Million - $70.8 Million
316,096 Added 44.23%
1,030,835 $226 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $95.4 Million - $107 Million
573,869 Added 407.37%
714,739 $121 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $543,048 - $628,030
3,299 Added 2.4%
140,870 $25.8 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $122 Million - $145 Million
-745,952 Reduced 84.43%
137,571 $0
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $8.31 Million - $10.5 Million
54,690 Added 6.6%
883,523 $146 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $117 Million - $134 Million
-696,560 Reduced 45.66%
828,833 $0
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $109 Million - $127 Million
749,719 Added 96.65%
1,525,393 $0
Q1 2018

May 11, 2018

SELL
$151.6 - $177.13 $142 Million - $166 Million
-938,586 Reduced 54.75%
775,674 $126 Million
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $50.3 Million - $57 Million
366,651 Added 27.21%
1,714,260 $257 Million
Q3 2017

Nov 09, 2017

BUY
$148.13 - $162.24 $200 Million - $219 Million
1,347,609
1,347,609 $205 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.